Tsingke Biotech
Tsingke Biotech is a Beijing-based, privately held DNA and RNA synthesis services company operating an integrated 'Gene Factory' platform that delivers custom genes, oligos, proteins, antibodies, and viral vectors to over 300,000 research institutions and biopharmaceutical customers globally.
- Company typePrivate
- Founded2017
- HeadquartersBeijing, China
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Tsingke Biotech does
Beijing Tsingke Biotech Co., Ltd. is a privately held Chinese biotechnology company founded in 2017 that operates an integrated DNA and RNA synthesis services platform branded as the 'Gene Factory'. The company produces phosphoramidites, enzymes, and buffers in-house and operates self-developed synthesis instruments ranging from 12-channel to 768-channel configurations, enabling an integrated workflow from raw reagents through GMP-grade oligonucleotide, gene, protein, antibody, and viral vector deliverables. Sub-brands Tsynth, Tsecure, ProLong, and Gene Factory segment the offering across standard gene synthesis, secure/IP-protected synthesis, extended-length synthesis, and the broader platform.
Tsingke serves over 300,000 cumulative customers spanning academic researchers, research institutes, biotech startups, and biopharmaceutical companies, with disclosed logos concentrated in global universities (University of Virginia, Aarhus, Macquarie, Florida, Eindhoven, Queensland, Groningen, KAUST, Helsinki, Málaga), cancer research centers (VIB-KU Leuven), and life sciences distributors (Avantor). The platform addresses use cases in antibody drug discovery, molecular diagnostics, vaccine development, gene editing, gene therapy, and agricultural biotech through application-specific landing pages and standardized service packages.
The business model is B2B project-based services revenue, quote-driven with no public list pricing, supported by a sales-led go-to-market combining direct sales (with representatives in Beijing Yizhuang and Tianjin), digital self-service quote requests, and industry conference presence (TIDES USA, AACR, BIO-Europe, Festival of Biologics). The company has raised approximately $88.9 million across two 2022 rounds and operates from a 70,000 m² footprint with GMP-compliant facilities in Beijing and Suzhou.
Tsingke Biotech firmographics
Firmographics- Name
- Tsingke Biotech
- Legal name
- Beijing Tsingke Biotech Co., Ltd.
- Website
- https://tsingke.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Tsingke Biotech is a Beijing-based, privately held DNA and RNA synthesis services company operating an integrated 'Gene Factory' platform that delivers custom genes, oligos, proteins, antibodies, and viral vectors to over 300,000 research institutions and biopharmaceutical customers globally.
- Ownership category
- akta.pro rank
Tsingke Biotech industry classification
Industry- Product category
- DNA/RNA Synthesis Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
- akta.pro secondary industries
- Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD)
Keywords
Where Tsingke Biotech is headquartered
LocationHeadquarters
- HQ city
- Beijing
- HQ country
- China
- HQ region
- Asia
Offices4 records
Markets served
Tsingke Biotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure, Marketing or Sales
Revenue model
- Gene Synthesis Services: Custom gene synthesis from fragments to full-length genes with codon optimization, cloning, and expression-ready formatting. Revenue generated through project-based pricing per synthesis request.
- Oligo Synthesis Services: Custom DNA and RNA oligonucleotide synthesis with flexible scales, modifications, and QC options for qPCR, cloning, sequencing, gene editing, and diagnostic applications.
- Protein & Antibody Services: Custom protein expression, purification, and antibody production using E. coli, mammalian, or baculovirus systems with quality analytics and scalability.
- Viral Vector Packaging: Plasmid prep, lentiviral packaging, AAV production, and LNP-formulated RNA services tailored for gene therapy, vaccine R&D, and in vitro functional studies.
- Gene Delivery Services: Gene delivery solutions including virus packaging for AAV, LV, and AdV formats.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | First Order Promotion |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Tsingke Biotech product offering
Product offeringCore offering
Tsingke Biotech operates an integrated "Gene Factory" platform that delivers custom DNA and RNA synthesis services, including oligonucleotides, gene synthesis, protein expression, antibody services, and viral vector packaging. The company combines in-house reagent production (phosphoramidites, enzymes, buffers) with proprietary 12 to 768-channel synthesis instruments and automated workflows to serve research institutions and biopharmaceutical companies worldwide with scale ranging from 2nmol laboratory grade to 12mmol industrial GMP-grade production.
Differentiator
Problem solved
Functional benefit
Brands
- Tsynth: Gene synthesis service brand
- Tsecure
- ProLong
- Gene Factory
Products and services
- Custom Oligonucleotide Synthesis
- Gene Synthesis (Tsynth)
- Gene Cloning Services
- saRNA and circRNA Synthesis
- IVT mRNA Synthesis
- Protein Expression and Purification Services
- Antibody Discovery and Production Services
- Viral Vector Packaging Services
- Zero-Contact Sequences System
- Next-Generation Rapid Protein and Antibody Solutions
Quantifiable outcome
- Protein generation within 3 days
- +3 more outcomes
Companies that use Tsingke Biotech
Customer profileNamed customers12 records
Segments6 records
Ideal customer profiles4 records
Tsingke Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
Tsingke Biotech partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- iGeneTech Bioscience Co., Ltd.coreStrategic partnership combining Tsingke's gene synthesis capabilities and integrated industrial chain (from 2nmol laboratory scale to 12mmol industrial scale) with iGeneTech's Ignite 3.0 high-throughput synthesis platform processing oligo pools from 4k to 650k in size with error rates as low as 0.2%. The collaboration targets precision medicine, bio-breeding, and gene editing markets with the goal of developing an integrated system spanning from synthesis to application.
- Zhejiang UniversitycoreJoint laboratory collaboration agreement to advance small nucleic acid drug delivery research. Combines Tsingke's synthesis capabilities with Zhejiang University's academic research expertise.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Tsingke Biotech competitors and assessment
Company assessmentDirect peers
- GenScript: GenScript is a global biotech offering gene synthesis, oligo synthesis, protein/antibody services, and viral vector packaging—the same end-to-end CDMO model as Tsingke's Gene Factory. It is the closest head-to-head competitor across nearly every revenue stream Tsingke operates in.
- Twist Bioscience: Twist Bioscience is a US-based DNA synthesis leader using silicon-platform writing technology, with overlapping oligo synthesis, gene synthesis, and DNA data storage offerings. It is a direct competitor in synthetic DNA manufacturing and NGS oligo pools, where Tsingke's iGeneTech partnership (Ignite 3.0) explicitly competes.
- Integrated DNA Technologies (IDT): IDT, owned by Danaher, is a market leader in custom DNA/RNA oligo synthesis, modifications, and qPCR/NGS reagents. It directly competes with Tsingke's core oligo synthesis and IVD-grade probes/primers businesses across academic and diagnostic customers globally.
- Synbio Technologies: Synbio Technologies is a gene synthesis and synthetic biology CDMO offering gene synthesis, oligo pools, and protein services. It is a direct comparable in the synthetic biology services market, particularly competing in Asia-Pacific and global academic accounts.
- Bioneer: Bioneer is a Korean biotech offering custom oligo synthesis, gene synthesis, and molecular diagnostics reagents. It directly competes with Tsingke in custom DNA/RNA synthesis and IVD probe/primer manufacturing, particularly in APAC.
- ATUM (formerly DNA2.0): ATUM is a synthetic biology company offering gene synthesis, protein engineering, and antibody discovery services. It overlaps with Tsingke's gene synthesis, protein expression, and antibody discovery offerings, particularly for early-stage biotech and academic customers.
- iGeneTech Bioscience: iGeneTech is a Chinese NGS oligo pool and target capture probe provider, partner of Tsingke via the Ignite 3.0 integration. It is a direct comparable in high-throughput oligo pool synthesis and a strategic partner/co-competitor in NGS oligos and target enrichment.
Broad incumbents
- Eurofins Genomics: Eurofins Genomics is the genomics services arm of Eurofins Scientific, offering oligo synthesis, gene synthesis, sequencing, and genotyping at large scale. It is a broad incumbent with overlapping capabilities but serves a wider portfolio including sequencing and routine genomics testing.
- Thermo Fisher Scientific: Thermo Fisher provides oligo synthesis (via Invitrogen), gene synthesis services, and a broad life sciences portfolio. It is a broad incumbent competing on scale, catalog offerings, and bundled procurement contracts rather than Tsingke's custom CDMO model.
Emerging players
- Bio Basic: Bio Basic is a Canadian-China based provider of custom oligo synthesis, gene synthesis, and peptide services. It is an emerging player with overlapping offerings, competing primarily on price in commodity oligo and gene synthesis markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Tsingke Biotech social profiles
Digital presenceTsingke Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tsingke Biotech leadership team
Management profileNumber of profiles
Profiles2 records
Tsingke Biotech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tsingke Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tsingke Biotech
What does Tsingke Biotech do?
Tsingke Biotech operates an integrated "Gene Factory" platform that delivers custom DNA and RNA synthesis services, including oligonucleotides, gene synthesis, protein expression, antibody services, and viral vector packaging. The company combines in-house reagent production (phosphoramidites, enzymes, buffers) with proprietary 12 to 768-channel synthesis instruments and automated workflows to serve research institutions and biopharmaceutical companies worldwide with scale ranging from 2nmol laboratory grade to 12mmol industrial GMP-grade production.
Is Tsingke Biotech a public or private company?
Tsingke Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Tsingke Biotech founded?
Tsingke Biotech was founded in 2017. It employs 11 to 50 people.
Where is Tsingke Biotech based?
Tsingke Biotech is headquartered in Beijing, China, in the Asia region.
How does Tsingke Biotech make money?
Five revenue lines are on record. Gene Synthesis Services are the primary driver. The others are oligo Synthesis Services, protein & Antibody Services, viral Vector Packaging and gene Delivery Services.
Who are Tsingke Biotech's main competitors?
Direct peers on record are GenScript, Twist Bioscience, Integrated DNA Technologies (IDT), Synbio Technologies, Bioneer, ATUM (formerly DNA2.0) and iGeneTech Bioscience. Broad incumbents are Eurofins Genomics and Thermo Fisher Scientific. Bio Basic is listed as an emerging player.
Does Tsingke Biotech have an API?
No public API is recorded for Tsingke Biotech.
What industry is Tsingke Biotech in?
Tsingke Biotech's product category is DNA/RNA Synthesis Services. Its primary akta.pro industry code is HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA), with a secondary code of HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services. Its NAICS code is 541714 and its SIC code is 8731.